🇺🇸 FDA
Pipeline program

Placebo to ARGX-119 concentrate for solution for infusion, ARGX-119

ARGX-119-2303

Phase 2 small_molecule active

Quick answer

Placebo to ARGX-119 concentrate for solution for infusion, ARGX-119 for Amyotrophic Lateral Sclerosis (ALS) is a Phase 2 program (small_molecule) at Argenx with 1 ClinicalTrials.gov record(s).

Program details

Company
Argenx
Indication
Amyotrophic Lateral Sclerosis (ALS)
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials